Oregon’s public universities, classified workers narrowly avoid strike – Oregon Public Broadcasting

By Sep 28, 2026

Labor — Oregon’s public universities, classified workers narrowly avoid strike Oregon Public Broadcasting – OPB

Auto-published by the finit.news Events monitor from Labor; summarized by AI and may contain errors — verify against the primary source. September 28, 2026.

By

Labor

Strike averted at UO as union and universities reach late deal – Lookout Eugene

Sep 28, 2026

Labor

Strike imminent at UO; union says universities failed to make ‘acceptable offer’ – Lookout Eugene

Sep 28, 2026

Labor

Italian port workers begin 24-hour national strike

Sep 28, 2026

Labor

Oregon’s public universities, classified workers narrowly avoid strike – Oregon Public Broadcasting

Regulatory Approvals

FDA Approves Zilurgisertib, an Oral ALK2 Inhibitor, for FOP

Regulatory Approvals

Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz

Regulatory Approvals

Oregon’s public universities, classified workers narrowly avoid strike – Oregon Public Broadcasting

By

Financial News For All

Oregon’s public universities, classified workers narrowly avoid strike – Oregon Public Broadcasting

FDA Approves Zilurgisertib, an Oral ALK2 Inhibitor, for FOP

Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz

FDA Approves AbbVie’s Juvmo for Parkinson Disease

Oregon’s public universities, classified workers narrowly avoid strike – Oregon Public Broadcasting

By

Related Post

Strike averted at UO as union and universities reach late deal – Lookout Eugene

Strike imminent at UO; union says universities failed to make ‘acceptable offer’ – Lookout Eugene

Italian port workers begin 24-hour national strike

Financial News For All

Oregon’s public universities, classified workers narrowly avoid strike – Oregon Public Broadcasting

FDA Approves Zilurgisertib, an Oral ALK2 Inhibitor, for FOP

Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz

FDA Approves AbbVie’s Juvmo for Parkinson Disease